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Summary Flow cytometry has enabled the objective assessment of cellular morphology and activity, which
can also be biochemically evaluated by measuring products of cellular metabolism, such as cyclic 3'5'
guanosine monophosphate (cGMP). Using paraffin-embedded formalin-fixed material obtained from the
primary operation, an analysis of the correlation between nuclear ploidy and the proliferative index (PI) as
quantified by flow cytometry with pre-treatment urinary cGMP was performed in 40 epithelial ovarian cancer
(EOC) patients. The majority of the study group had advanced disease (28 FIGO III/IV) and residual disease
(31). All but three (stage I) patients received single agent high dose cisplatinum as first-line therapy
(100 mg m2 x 5); in patients with evaluable disease there was a response rate of 64%. Thirty-one patients
have died; the median survival of the study population being 27 months. There was a significant association
bet een cGMP and PI. Significantly more aneuploid tumours had elevated PI values (P= 0.02). No variable
pr&licted response. An initial univariate log rank analysis identified stage, the amount of residual disease,
cGMP and PI as prognostic factors. Because of the interrelation between these and other factors and because
PI did not conform to the proportional hazards model, a multivariate stepwise discriminant analysis was
performed using survival at 36 months (the minimum follow-up for surviving patients) as the end-point. On
the basis of this analysis, stage and residual disease were the most important prognostic factors, but cyclic
GMP continued to have prognostic value even when these other factors were entered into the predictive
model. However, the additional information gained has little clinical relevance.
Despite the use of more radical surgery and the advent of
active chemotherapy, the long-term prognosis in epithelial
ovarian cancer (EOC) is still largely determined by tumour
characteristics rather than by the treatment administered.
While many patients with early disease may remain disease-
free following primary surgery, the majority of patients
present with advanced disease, which is not amenable to
complete surgical extirpation. In these patients further treat-
ment must realistically be regarded as palliative. Chemo-
therapy is now the standard treatment in such patients
(Blackledge et al., 1987) and although response rates as high
as 90% have been reported using cisplatinum containing
regimens (Williams et al., 1985), these results have not been
translated into significant improvements in survival. Never-
theless some patients will derive considerable short-term
benefit. Such active chemotherapy can be toxic so it is
desirable to be able to select patients likely to benefit and
likewise to use more appropriate therapy in poor-risk
patients.
Currently therapeutic decisions are largely based on FIGO
staging, residual disease status after primary surgery and
performance score, which can be regarded as indirect
manifestations of tumour biology (Redman et al., 1986).
Assessment of conventional tumour characteristics, such as
histological type and grade are of value but are subjective
and are confounded by tumour heterogenicity.
The advent of flow cytometry has facilitated objective
assessment of tumour cell morphometry. These studies have
largely evaluated ploidy, and S-phase fraction (Friedlander et
al., 1984a,b; Blumenfeld et al., 1987; Rodenburg et al., 1987;
Fowler et al., 1988). The proliferative index (PI) is used to
characterise the proliferating cells present in the tumour. This
parameter is estimated by the percentage of cells having a
DNA content greater than GO/GI phase. A number of inves-
tigators have indicated that PI has significant potential as a
predictor of prognosis for patients with cancer. It has been
correlated with prognosis in breast cancer (McGuire &
Dressler, 1985). Aneuploid tumours tend to have a higher
S-phase fraction when compared to diploid tumours (Kal-
lioniemi et al., 1987), but few data are available on P1 as a
prognostic variable in ovarian cancer.
In addition to morphological studies it is also possible to
quanitify indirectly tumour activity by the assay of products
of cellular metabolism. Cyclic guanosine 3':5' monophos-
phate (cGMP) has been evaluated in this respect. Urinary
cGMP levels correlate with tumour bulk (Turner et al.,
1982). In addition to this observation, Luesley et al. (1986)
noted an independent effect of elevated urinary cGMP levels
on survival in patients with residual epithelial ovarian cancer.
Many workers have previously noted relationships between
cGMP metabolism and cellular growth (Kupetz & Jeter,
1983; Seifert & Rudland, 1974; Weinstein et al., 1974; Zeilig
& Golberg, 1977). This relationship viewed alongside the
clinical observation of a non-volume dependent effect on
survival lead to the hypothesis of cGMP being a marker for
tumour activity rather than volume. In order to test the
hypothesis that elevated levels of cGMP do in fact represent
increased tumour cell activity and to evaluate the indepen-
dent prognostic value of cGMP, ploidy and S-phase fraction
this study was performed.
Materials and methods
Patients
The study group comprised 40 patients with histologically
proven EOC who had had postoperative, pretreatment
urinary cGMP levels assayed and in whom there was archive
histological material available to enable the cytometric
studies to be performed. This cohort of patients had been
recruited into an earlier study evaluating cGMP as a tumour
marker in EOC (Luesley et al., 1986). Entry criteria included
age (below or equal to 70), histological confirmation of EOC
(borderline tumours were excluded), no previous therapy,
satisfactory staging and maximal possible primary surgical
debulking. The characteristics of the study group are sum-
marised in Table I.
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All patients were staged according to the FIGO
classification (Peterson et al., 1985). The disease status at the
end of primary surgery was recorded in detail for all patients.
Histological material was centrally reviewed and classified
using WHO criteria (Serov et al., 1973). All patients were
managed by one of the authors (D.M.L.) according to
specified treatment protocols. Patients with FIGO stage I
disease received no further treatment, whilst all other patients
received up to five courses of single agent cisplatinum
(100 mg m 2) as primary treatment, administered at 3-weekly
intervals. Response was assessed clinically by at least two
observers and radiologically, using ultrasound/CT scan where
appropriate.
cGMP assays
The assay method and performance has been previously des-
cribed (Luesley et al., 1986). A cut-point of 90 nmol mmol '
creatinine was used, a level exceeded by 1% of normal
controls.
Flow cytometry
Paraffin-embedded material was available on all patients. All
tissue had been formalin fixed and processed using standard
histological techniques. Thirty gsm sections were supplied
from each block by the pathology department responsible for
the original histopathological preparation and diagnosis.
These sections were taken from blocks containing >70%
tumour cells and an adjacent 5 gm haematoxylin and eosin
stained section was also supplied from each block to ensure
adequate tumour presence.
Single cell suspensions were prepared using the method of
Hedley et al. (1983), with minor modifications. Two 30 lm
sections were dewaxed in xylene and rehydrated through
graded alcohol (100%, 90%, 70%, 50%) into distilled water.
The sections were treated with a 1% pepsin solution
(pH = 1.5) for 30-60 min at 37°C with vortex agitation. Cell
counts were then performed using a haemocytometer and
provided more than 105 cells ml' were present, the suspen-
sion was centrifuged at 2,500 r.p.m. for 10 min. The resulting
pellet was resuspended in 1 ml 10-2 M Tris (2-amino-2-
(hydroxymethyl) propane 13,3-diol (tris)) (Analar BOH),
pH 7.0, containing 5ltM MgCl2 (BOH) as described by
Deitch et al. (1982). Specimens were filtered through 100jtm
pore size nylon gauze (cadisch) before storage at 4°C.
Immediately preceding analysis specimens were stained using
a modification of the method of Goh et al. (1986). Briefly,
0.5 ml propidium iodide (propidium iodide-conc. I mg ml'
in Tris buffer pH 7.0, sigma) with 0.5 ml ribonuclease type
I AS (RNAse) (2 mg ml-' in Tris buffer pH 7.0, sigma) was
added to remove double stranded RNA stained by the pro-
pidium iodide and incubated for 15 min at 37°C. Cell clump-
ing and overestimation of the S-phase fraction was reduced
by passing the suspension through a 25 gauge needle several
times (Camplejohn et al., 1985), prior to filtration through a
35 tim pore size nylon gauze. A record of each sample was
made by placing a drop on a slide allowing it to air dry prior
to staining by Papanicolaou's method.
Nuclear DNA content was measured using a Becton
Dickenson FACS 440 cell sorter with an argon ion laser light
source (laser excitation 200 mW at 488 nm, spectral physics).
The instrument was aligned using chicken red blood cells (c
RBC) and propidium iodide coated beads, before and after
analysis of the samples. Thirty thousand nuclei were analysed
at a rate of 700 per second, with low fluorescent particles
gated out of the analysis.
Cell cycle analysis and calculation of the coefficient of
variation (CV%) were performed using software supplied by
Becton Dickinson. The CV% was calculated for each G,
peak as a meaasure of the technique's ability to resolve two
closely situated GI peaks (DI< 1.1). Histograms having a
CV% >8 were excluded from the analysis as being unsatis-
factory and were not regarded as being indicative of aneu-
ploidy. The DNA index (DI) was calculated as the ratio of
multiple G, peaks to the G, diploid in channel numbers (DI
1.0= single diploid GI). The proliferative index (PI) was
calculated as the summation of all nuclei in the S and G2
phases of the histogram. Tumour cells sharing a common G,
peak with normal cells were defined as diploid (DI= 1.0) but
those possessing one or more extra peaks were defined an
aneuploid (DI> 1.0). Aneuploidy was thus defined when
tumours had obvious discernible separate GO/G, peaks with a
DNA index greater than 1.0. Tumours possessing G2 peaks
containing more than 15% of the total cells were graded as
diploid with a high PI and were not considered aneuploid.
Proliferative index was calculated from the summation of all
nuclei in the S and G2 phases of the histogram and is defined
in this study the the equation
PI=S+ G2/G, + S + G2x 100
In the case of aneuploid tumours or histograms shqwing two
separate G, peaks, the cell kinetics data were determined
only for the aneuploid subpopulations of the tumour.
Statistical methods
All patient data was stored using the facilities of the West
Midlands Cancer Research Campaign Trials Unit. The statis-
tical analyses were performed using the BMCP (Biomedical
Programs, Los Angeles, California) statistical software
(Dixon, 1988). The differences in survival between groups
tested using the log rank test (Peto et al., 1977). A multi-
variate stepwise discriminatant analysis of outcome was per-
formed using survival at 36 months as the end-point.
Results
In patients with evaluable disease (n = 25), there was a
clinical response rate of 64% (16/25), eight of whom had a
complete clinical response. Thirty-one patients have died and
the median survival is 27 (95% confidence limits 20-34)
months. The median time on-study is 46 months.
The median CV% was 6.3 (range 3.7-7.8; mean 6.01).
Nine tumours were aneuploid. There was no significant
association between ploidy and other conventional prognos-
tic factors, including stage, bulk of residual disease, his-
tological type and grade, although all the mucinous tumours
were diploid (Table II). There was a substantial negative
correlation between aneuploidy and the amount of pos-
toperative disease, although this failed to reach formal levels
of statistical significance.
The distribution of PI appeared bimodal and a cut-point
of 40% was used to categorise the data (Figure 1). The
relationship between PI and other prognostic variables is
summaried in Table III. Overall the mean PI was 36%
(range = 6-89). All the mucinous tumours had a PI of lessBIOCHEMICAL AND CYTOMETRIC INDICES IN OVARIAN CANCER 757
Table II Distribution of DNA ploidy status according to stage,
histological grade, differentiation, residual disease status, cGMP levels
and PI
DNA ploidy status Fisher's exact
Diploid Aneuploid test (two tail) r
Stage
I/II 8 4 0.411 -0.17
hIII/I 23 5
Residual disease status
< 2 cm 9 6 0.057 - 0.33
>2cm 22 3
Histological type
mucinous 6 0 0.307 0.23
non-muc. 25 9
Differentiation
well/mod. 16 3 0.457 0.15
poor 15 6
cGMP
> 90 17 8 0.117 0.29
PI












u) Lo t LO LO L O) LO
CN CD '1 LO r- co
Proliferative index (%)
Figure 1 Distribution of proliferative index.
Table III Distribution of PI according to stage, histological grade,
differentiation, residual disease status and cGMP levels
Proliferative index Fisher's exact
<40% >40% test (two tail) r
Stage
I/IV 6 6 0.729 -0.10
III/IV 17 11
Residual disease status
< 2 cm 9 6 1.000 0.04
>2cm 14 11
Histological type
mucinous 6 0 0.030 0.36
non-muc. 17 17
Differentation
well/mod 14 5 002 03 poor 9 12 0.062 0.31
cGMP
> 90 12 14 0.046 0.35
than 40% (P = 0.03). There was a significant association
(P = 0.046) between elevated PI and cGMP levels (Figure 2).
Although significantly more aneuploid tumours had elevated
PI values (P = 0.02; r = 0.39) there was no significant
association between ploidy and cGMP overall (P = 0.1 17;
r = 0.29). However, in patients with less than 2 cm residual
disease aneuploid tumours had higher cGMP levels (Fisher
exact test P = 0.04).
In those patients evaluable for response to treatment no
single prognostic variable independently predicted response.
In terms of survival, however, FIGO stage, disease residuum,










< 4U > 4U
Proliferative index (%)
Figure 2 Association between proliferative index and cGMP levels.
(Table IV). Because of the possible interrelationships between
these and other variables, and because PI did not conform to
the proportional hazards model, a multivariate stepwise dis-
criminant analysis was performed. On the basis of this
analysis the most important prognostic variables were stage
and residual disease after primary surgery. A predictive
model based on these variables alone correctly predicted
survival status at 36 months with an accuracy of 85%.
Having entered these variables into the model cGMP con-
tinued to have an independent but limited prognostic value.
This is reflected by the increase in predictive accuracy of
survival status at 36 months to 87% when used in conjuction
with residual disease to classify patients (Table V).
The classification scores (SI and S2) were calculated from
weights for stage, residual disease and cGMP derived from
the analysis as follows:
S1 = score for patient classification into 'alive' group
= 15.4 + 9.1 x (cGMP value) + 8.6 x (residual disease
value) + 4 x (stage value)
S2 = score for patient classification into 'dead' group
= 32.6 + 12.5 x (cGMP value) + 13.3 x (residual disease
value) + 6.4 x (stage value)
where patients with cGMP levels less than or equal to 90
have a value of 0, and greater than 90 a value of 1; residual
disease less than 2 cm a value of 0 and greater than 2 cm a
value of 1; and FIGO stage I/TI a value of 0 and FIGO stage
III/IV a value of 1.
Discussion
Only nine patients (22%, 95% confidence limits 8-36) had
aneuploid tumours, which is a lower figure than previously
reported for malignant epithelial ovarian cancers. For exam-
ple, in a recent review of the literature, Tattersall (1987)
reported that 62% of all malignant epithelial ovarian cancers
were aneuploid, and this figure was probably higher in stage
II and IV patients. The absence of a demonstrable relation-
ship between tumour cell ploidy and grade of differentiation
is also contrary to the findings of previous studies (Feichter
et al., 1985). The reason for these discrepancies is not clear
and may be a function of the small size of the study group
and/or our stringent definition of aneuploid histograms as
described earlier. Tumour ploidy was not a prognostic factor
as have been previously reported in two large studies (Hedley
et al., 1985; Rodenberg et al., 1987). However, these studies
had a larger proportion of early stage (FIGO I/II) patients
and it is clear that the prognostic significance of ploidy is
reduced in more advanced tumours (Kallioniemi et al., 1988);
indeeed in stage IV patients it ceases to have prognostic value
(Tattersall, 1987).
The significant association between PI and cGMP suggests
that they may reflect a common parameter, namely that of
tumour cell activity. On the basis of PI criteria, the study
group be categorised into two sub-populations. PI was758 C.W.E. REDMAN et al.
Table IV Results ofunivariate analysis and F-to-enter values at 'step
0' in discriminant analysis
Dead (% at
Variable No. 36 months) X,2 P F-to-enter
Stage
I/Il 12 6 (42) 10.8 0.001 21.85
III/IV 28 27 (89)
Residual disease status
<2 cm 15 9 (47) 8-41 0.004 18.47
>2cm 25 24 (96)
cGMP
( 90 15 10 (60) 3.26 0.07 4.48
> 90 25 23 (88)
PI
> 40 23 17 (69) 2.5 0.11 1.95
>40 17 16 (88)
Histological type
mucinous 6 4 (67) 0.45 0.51 0.81
non-mucinous 34 29 (79)
Differentiation
well/mod. 19 16 (62) 0 31 0.57 0.04
poor 21 17 (75)
DNA ploidy
diploid 31 25 (60) 0.15 0.7 0.00
aneuploid 9 8 (79)
significantly higher in aneuploid tumours, as has been de-
scribed before (Christov et al., 1987), but the relationship of
ploidy with cGMP was less marked. In this respect it must be
remembered that as a marker of tumour cell activity, urinary
Table V Predictive accuracy ofsurvival status at 36 monthsusing the
classification function derived from stage, residual disease status (andif
cGMP is included)
Predicted status
Actual status Alive Dead Total % correct
Alive 7(8) 2(1) 9(9) 77.8(88.9)
Dead 4(4) 27(27) 31(31) 87.1(87.1)
Total 11(12) 29(28) 40 85.0(87.5)
cGMP levels is relatively non-specific as it is influenced by a
number of factors, including tumour bulk (Luesley et al.,
1986). The observation that cGMP may have more prognos-
tic weight than PI may be a function of this. The fact that
22% of the study group were classified as FIGO stage II
would suggest that understaging was likely, and therefore
might also apply to the assessment of post-operative disease.
In this respect cGMP levels may contribute additional value
about post-operative status.
These data indicate that increased tumour cell activity,
reflected by elevated cGMP and PI values, has some adverse
prognostic significance, but of less relevance than that of
FIGO stage and postoperative tumour bulk. In clinical terms
the additional information contributed by tumour cell
activity would appear to have little current application in the
management of advanced ovarian cancer. The conclusions
drawn from this preliminary study, limited by the relatively
small number ofpatients studied, need to be substantiated by
further evaluation.
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